More Protein. Uneven Profits.
Why rising protein demand produces different earnings for Glanbia and BellRing.
Download PDFReflexivity Theme Observatory · GLP-1 · Evidence as of 28 Sep 2026
GLP-1s are changing demand. Who captures the earnings?
Roughly one in five US households now includes a GLP-1 user. This report follows that shift past the drug makers to 67 companies, from protein suppliers to sleep-apnea devices, and tests where it is reaching earnings.
How we built it
Reflexivity's Knowledge Graph covers 800+ themes and maps how companies connect to themes, products and each other. We used it to trace GLP-1 through the market, then tested each connection against company results, policy data and patient studies.
Research question
What must become true for broader, increasingly oral and cash-pay GLP-1 adoption to change earnings of companies outside drug manufacturers?
Two focused briefs
The Patient Journey Is Changing
What wider access means for prescription platforms, companion care and sleep treatment.
Download PDF30-second orientation
Four facts set the scale and the limit
Adoption is broad enough to affect household behavior. Earnings transmission still depends on revenue concentration, competitive structure, input costs and whether the operating channel is substituted or expanded.
~1 in 5
US households using GLP-1sThe treated cohort is now large enough for category effects, but not for automatic company-level attribution.
Evidence: EV-008–010
$149
Oral starting priceCash-pay pills broaden access while employer and Medicaid1 obesity coverage remains constrained.
Evidence: EV-001–007
−5.3%
Grocery spend per adopterAn illustrative aggregate drag is roughly 1% before discontinuation.
Evidence: EV-010, EV-014
1 Medicaid: US federal–state health coverage for eligible people with limited income.
Exposure landscape
Direction is visible - but only after separating demand from earnings
Current evidence supports three positive and three negative operating signals. Counterexamples prevent a simple long-protein / short-snacks interpretation.
Positive exposure
Positive operating signals
Glanbia (GL9): Optimum Nutrition +25.2% in H1; FY2026 earnings guidance raised.
ResMed (RMD): Sleep & Breathing Health +9%.
Omada Health (OMDA): members +45%; guidance raised.
Negative exposure
Negative operating signals
Medifast (MED): revenue −75% from FY2021–FY2025.
Simply Good Foods (SMPL): Atkins −24.6%.
Inspire Medical Systems (INSP): revenue −7.6%, with reimbursement confounding.
Counterexamples and insulation
BellRing Brands (BRBR) has healthy demand but weaker earnings.
Lindt & Sprüngli (LISN), Monster Beverage (MNST) and Coca-Cola (KO) challenge the simple food-and-drink short thesis.
Hims & Hers (HIMS) and GoodRx (GDRX) remain conditional access exposures.
Causal story
Access expands. Business models determine who benefits.
Cash-pay and temporary Medicare2 access widen use while commercial coverage remains sticky. The Medicare GLP-1 Bridge is a temporary access program for eligible Part D3 beneficiaries. The effects then split: pressure on diet programs, stronger protein demand and changes in treatment and companion care.
Access → operating channel → companyDecision map
PositiveNegativeConditionalAmbiguous / insulatedControl / comparatorMechanismSplit groupArrow color = target’s exposureGrey = unsigned or mixed target
Swipe sideways to follow the full map.
2 Medicare: US federal health insurance, primarily for people age 65 and older.
3 Part D: Medicare’s prescription-drug benefit.
Most informative conditional connection
Protein demand is rising; branded-protein earnings can still fall
Rising protein demand can benefit whey suppliers while higher ingredient costs and heavier promotion squeeze branded producers, including ready-to-drink (RTD) shake brands. Glanbia and BellRing illustrate that divergence; the evidence does not establish a direct supply relationship between them.
Two storylines · proteinSupplier capture versus branded margin
PositiveNegativeControl / comparatorMechanismArrow color = target’s exposureGrey = unsigned or mixed target
Swipe sideways to follow the full map.
Treatment pathway
Sleep-treatment evidence points in two directions
Positive airway pressure (PAP) uses pressurized air to keep airways open during sleep; CPAP is one type of PAP. ResMed’s claims analysis finds PAP initiation 10.8 percentage points higher among obstructive sleep apnea (OSA) patients prescribed a GLP-1, with higher resupply. A separate Komodo analysis finds lower CPAP initiation after tirzepatide. Inspire’s near-term weakness is real but confounded by coding, and management sees a long-term pipeline catalyst as more high-BMI patients qualify.
Two storylines · sleep apneaCPAP initiation versus implant timing
PositiveNegativeConditionalMechanismArrow color = target’s exposureGrey = unsigned or mixed target
Swipe sideways to follow the full map.
Food, drink and consumer counterexamples
Lower calories do not imply uniformly lower company revenue
Premium products, functional drinks, smaller portions and diversified portfolios can cushion lower consumption. Acquisitions can also change the investment outcome.
CounterexamplesWhere the simple food thesis breaks
Ambiguous / insulatedControl / comparatorMechanismContext / not establishedArrow color = target’s exposureGrey = unsigned or mixed target
Swipe sideways to follow the full map.
Rare connections
Four transfers worth monitoring
Each connection pairs a transmission path with a result to watch.
Whey moves value upstream
High-end whey demand and pricing benefit the supplier layer while branded protein margins absorb input costs and promotion.
Evidence: EV-050–053, EV-066–067
Coverage retreat has a services loser
Lower prior-authorization activity could reduce McKesson (MCK) services-segment operating-income growth by 5–10%, based on an RBC estimate.
Evidence: EV-120
Premium can invert the food sign
Lindt-sponsored Circana data show GLP-1 users’ premium-chocolate sales up about 17% in 2025, against 6.5% for non-users. Selection bias remains.
Evidence: EV-026
Survival can add downstream volume
DaVita (DVA) frames lower mortality as a long-run dialysis-duration tailwind—a counterintuitive, unquantified path.
Evidence: EV-151
Company and channel evidence
Operating signal, counterevidence and gate
The table keeps structural exposure separate from the latest company result. A positive theme with a negative KPI remains a counterexample, not a beneficiary. Prices are 28 September 2026 intraday values.
| Company / role | Current signal | Counterevidence | Evidence gate |
|---|---|---|---|
| Glanbia (GL9) Positive exposure | H1 2026 Optimum Nutrition like-for-like +25.2%; strong protein-solutions pricing; FY2026 adjusted EPS growth guide raised at H1 to 17–20% at constant currency, from the upper end of 7–11% | Elevated whey costs squeeze Performance Nutrition margins; growth may be fitness/protein broadly rather than GLP-1 | Q3 2026 confirmation of sustained double-digit Optimum Nutrition growth and protein-solutions pricing |
| ResMed (RMD) Positive exposure | Sleep & Breathing Health +9%; claims data: PAP initiation 10.8 percentage points higher in GLP-1 users | Company-sponsored observational analysis; long-run OSA prevalence could fall | Independent claims replication; device growth ≥high single digit |
| Omada Health (OMDA) Positive exposure | Members +45% to 1.09M; company reports experience supporting 150,000+ GLP-1 members; FY26 revenue raised to $334–340M; adjusted EBITDA positive | Outcome data company-reported; payer concentration | GLP-1 track member disclosure; PBM4 channel retention |
| Medifast (MED) Negative exposure | Revenue −75% FY2021–FY2025; Q2 2026 sales $76.4M; Q3 guide $60–80M; OPTAVIA replaced by Trilivy | Pivot to metabolic health; director buying; small base | Trilivy coach productivity and revenue stabilization |
| Simply Good Foods (SMPL) Negative exposure | Sales −6.3%; Atkins −24.6%; gross margin −390bp (180bp restructuring); FY26 sales down 6–7%; price $9.455 | Quest and OWYN still grow modestly; Atkins weakness also reflects distribution losses and softer takeaway | Atkins stabilization; Quest growth >10% |
| Inspire (INSP) Negative exposure | Revenue −7.6%, US −9.6%; management cites GLP-1 headwind; coding/WISER confound | Reimbursement is co-driver; long-run BMI eligibility upside | US volumes after coding normalizes (tests whether weakness persists) |
| BellRing (BRBR) Control / counterexample | RTD dollar consumption +6%; sales beat; adjusted EPS $0.30 vs $0.37 consensus; adjusted gross margin 27.7%; category growth ~8%; 27% on promotion; price $7.71 | Scale competitors (fairlife, Muscle Milk), promotion intensity, whey/freight inflation; CEO change | Adjusted gross margin back above ~33% with promotion share falling; FY27 EBITDA guide |
| Lindt & Sprüngli (LISN) Control / counterexample | Company-sponsored Circana: GLP-1 users premium chocolate +~17% (2025) vs +6.5% non-users | Observational, company-sponsored, possible income/selection bias; volume vs price not separated | Independent panel (Numerator/Circana) replication by user cohort; FY2026 US volume by channel |
| Monster (MNST) Control / counterexample | Monster Energy +21.6%; US convenience-store share +1.1pts; international 46% | Zero-sugar mix and functional positioning insulate; not in the Reflexivity GLP-1 Ripple Effects theme | Energy category volume in GLP-1 households |
| Coca-Cola (KO) Control / counterexample | Global volume +5%, North America organic revenue +7%; fairlife Core Power competes with Premier Protein | Diversified portfolio; protein capture runs through fairlife | fairlife volume/capacity disclosures |
| Hims & Hers (HIMS) Conditional opportunity | >100k new weight-loss subscribers/month (management outlook, Q1 2026); Q3 revenue guide $880–900M; loss $0.37; gross margin pressure | FTC lawsuit (29 Jul 2026), Visa monitoring, class action; branded mix lowers margin | FTC resolution without injunction; GLP-1 revenue disclosure; margin stabilization |
| WW International (WW) Conditional opportunity | Clinical subscribers +55.7% to ~197k; clinical subscription revenue expected to represent 25–30% of FY2026 revenue; total revenue guide $620–635M | Legacy subscriber decline; figures from secondary reports of filings | Clinical revenue >30% and total revenue stabilization |
4 PBM: A company that administers prescription-drug benefits.
Evidence gates
What would change the classification
Each gate names what would confirm the current reading and what would overturn it.
Protein transfer
Confirm: Glanbia sustains double-digit Optimum Nutrition growth and whey pricing while BellRing margin remains below roughly 33%.
Invalidate: whey normalizes and branded margin recovers.
Evidence: EV-050, EV-066
Sleep split
Confirm: independent claims work reconciles CPAP initiation and Inspire volumes remain weak after coding normalizes.
Invalidate: ResMed starts decline or Inspire volumes recover with coding.
Evidence: EV-081–082, EV-166
Access and coverage
Confirm: cash-pay and the $50 Medicare Bridge add users while employer coverage stays near 36%.
Invalidate: the Bridge lapses after 2027 without a replacement.
Diet substitution
Confirm: Medifast and Atkins declines persist.
Invalidate: Medifast posts two sequential growth quarters or Atkins returns to growth.
Food resilience
Confirm: large-cap North American volumes remain positive above 25% household adoption.
Invalidate: cohort-adjusted category drag exceeds 2% and appears in issuer attribution.
Evidence: EV-010, EV-021, EV-035
What to watch next
Follow the transfer. Test it in earnings.
GLP-1s are reshaping more than appetite. They put pressure on diet programs, shift protein economics and alter routes into treatment and companion care. The next tests are concrete: supplier pricing versus branded margins, independent CPAP evidence, and durable growth in care and access platforms. Those results—not category labels—will determine where the earnings opportunity holds.
Reference
The full 67-entity universe
The main findings are above. Use the registry and six channel maps below to explore individual companies, their evidence and the results to watch. Each company appears once in these maps, under its primary channel.
Positive exposure (3): Glanbia (GL9), ResMed (RMD), Omada Health (OMDA).
Negative exposure (3): Medifast (MED), Simply Good Foods (SMPL), Inspire (INSP).
Conditional opportunity (8): Danone (BN), Hims & Hers (HIMS), WW International (WW), GoodRx (GDRX), Pernod Ricard (RI), Life Time Group (LTH), Magnum Ice Cream (MICC), International Flavors & Fragrances (IFF).
Control / counterexample (5): Lindt & Sprüngli (LISN), Monster (MNST), Coca-Cola (KO), BellRing (BRBR), Planet Fitness (PLNT).
Ambiguous / insulated (12): Mondelez (MDLZ), PepsiCo (PEP), Hershey (HSY), Keurig Dr Pepper (KDP), Herbalife (HLF), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), CVS Health (CVS), Cigna (CI), McDonald's (MCD), Constellation Brands (STZ), General Mills (GIS).
Research-only (24): Medtronic (MDT), Boston Scientific (BSX), Teladoc Health (TDOC), Centene (CNC), UnitedHealth Group (UNH), McKesson (MCK), Yum! Brands (YUM), Domino's Pizza (DPZ), Chipotle Mexican Grill (CMG), Sweetgreen (SG), Wingstop (WING), Diageo (DGE), Boston Beer (SAM), Walmart (WMT), Conagra Brands (CAG), Barry Callebaut (BARN), Coca-Cola FEMSA (KOFUBL), Nestlé (NESN), Performance Food Group (PFGC), United Airlines (UAL), DaVita (DVA), Zimmer Biomet (ZBH), AdaptHealth (AHCO), Dexcom (DXCM).
Excluded (6): Utz (UTZ), Want Want China (0151), Otsuka (4578), Lotus Bakeries (LOTB), Eli Lilly (LLY), Novo Nordisk (NOVO B).
Private / context and institutions (6): Huel (private), Intersnack Group (private), Ro (private), Centers for Medicare & Medicaid Services (institution), State Medicaid programs (institution), US employer plan sponsors (institution).
Reference · broader universeFood volume and mix
ConditionalAmbiguous / insulatedControl / comparatorMechanismContext / not establishedDashed = membership / unconfirmed
Swipe sideways to follow the full map.
Reference · broader universeProtein density and portion control
PositiveNegativeConditionalAmbiguous / insulatedControl / comparatorMechanismContext / not establishedDashed = membership / unconfirmed
Swipe sideways to follow the full map.
Reference · broader universeDiet programs, restaurants and alcohol
NegativeConditionalAmbiguous / insulatedMechanismContext / not establishedDashed = membership / unconfirmedRule = channel boundary
Swipe sideways to follow the full map.
Reference · broader universeSleep apnea and procedures
PositiveNegativeAmbiguous / insulatedMechanismContext / not establishedDashed = membership / unconfirmedRule = channel boundary
Swipe sideways to follow the full map.
Reference · broader universeVirtual care, reimbursement and coverage
PositiveConditionalAmbiguous / insulatedInstitutionMechanismContext / not establishedDashed = membership / unconfirmedRule = channel boundary
Swipe sideways to follow the full map.
Reference · broader universeCohort, transport and supplier adjacencies
ConditionalControl / comparatorMechanismContext / not establishedDashed = membership / unconfirmedRule = channel boundary
Swipe sideways to follow the full map.
Methodology
Methodology, caveats and sources
Evidence strength governs the language.
The analysis separates structural exposure, current operating signal, attributable catalyst and company materiality. Facts, enacted policy, surveys, observational studies, randomized trials and inference are labeled distinctly. First-order manufacturers are context only.
No weights are shown because volatility, liquidity, correlation, borrow and short-interest inputs were unavailable. Restaurants, alcohol, apparel and airlines lack company-level GLP-1 attribution. ResMed and Omada outcome evidence is company-sponsored; Glanbia’s bilateral relationship with BellRing is not documented.
ScopeThe maps trace changes in spending, margins and treatment activity. Company classifications separate structural exposure from current operating results; evidence gates identify the next test. These classifications are not portfolio weights.
Sources
EV-001–002 · CNBC; GoodRx — Wegovy pill and Foundayo cash-pay launch prices, Jan–Apr 2026
EV-005 · KFF — Medicaid coverage of GLP-1s for obesity, Jan 2026
EV-006 · IFEBP via CNBC — Employer survey, Jul 2026
EV-008, EV-011 · PwC — Analysis of Numerator GLP-1 consumer panel, May 2026: 21% of US households with a current user
EV-009 · Food Business News — Circana household data, 2026: 23% of US households with a user during the prior year (Fall 2025). This differs from current-use prevalence; both support an approximate one-in-five headline
EV-010 · Cornell / Journal of Marketing Research — Matched household panel
EV-026 · Reuters — Lindt-sponsored Circana chocolate data, 10 Mar 2026
EV-050 · BellRing — Q3 FY2026 results, 4 Aug 2026: Premier Protein RTD dollar consumption +6%; adjusted gross margin 27.7%; $10M excess-inventory charge (180bp). Reflexivity earnings recap confirms $0.30 adjusted EPS versus $0.37 consensus; checked 7 Oct 2026.
EV-052 · MT Newswires citing BofA — RTD shake category data, May 2026
EV-057 · Simply Good Foods — Q3 FY2026 results, 9 Jul 2026: Atkins sales −24.6%, reflecting distribution losses and softer takeaway; gross margin −390bp, including 180bp restructuring. Also cross-checked against Reflexivity’s earnings recap.
EV-059 · Reflexivity financial statements — Medifast FY2021–FY2025
EV-081 · Reflexivity earnings recap — Inspire Q2 2026
EV-082 · ResMed — January 2026 investor presentation, slide 11: PAP initiation +1,080bp (10.8 percentage points); three-year PAP resupply +620bp (6.2 percentage points). Company-sponsored observational claims analysis. Reflexivity relationship evidence uses rounded “11%” wording; the primary source controls the unit.
EV-083 · Reflexivity earnings recap — ResMed Q4 FY2026
EV-104 · Reflexivity earnings recap — Omada Q2 2026
EV-105 · Reflexivity relationship evidence — Omada describes its GLP-1 care model as informed by experience supporting 150,000+ GLP-1 members; company-reported, checked 7 Oct 2026. This does not establish current enrollment in individual programs.
EV-120 · MT Newswires citing RBC — McKesson services, 19 Aug 2026
EV-138 · The Lancet — Semaglutide alcohol-use-disorder trial, 2026
EV-151 · Reflexivity relationship evidence — DaVita, 2026
EV-164 · Glanbia — Q1 2026 interim management statement
EV-165 · Glanbia — 2026 Half Year Results, 6 Aug 2026: H1 Optimum Nutrition like-for-like revenue +25.2%; Dairy Nutrition adjusted EBITDA $92.3M versus $72.2M, supported by strong protein-solutions pricing; FY2026 adjusted EPS growth guidance 17–20% at constant currency. These H1 figures replace the earlier Q1 growth snapshot.
EV-166 · Komodo Health — Independent claims analysis of CPAP after tirzepatide, Feb 2026
EV-167 · National Restaurant Association — 2026 consumer survey
EV-168 · MT Newswires via Reflexivity news — Glanbia Posts Higher H1 Attributable Profit, Revenue, 6 Aug 2026
Run this analysis on your own holdings
Reflexivity is an AI investment research platform for institutional investors. Our Knowledge Graph maps how companies connect, so you catch the risks and opportunities you'd otherwise miss.
- Map any theme against your holdings, with every link traced to source
- Get alerts on what moved, why, and who else is exposed
- Works where you already do: our platform or your own environment via API and MCP
Disclaimer
This report is provided for information only and does not constitute investment advice or a recommendation to buy, sell or hold any security. Company classifications describe exposure to the GLP-1 theme and are not portfolio weights. Figures reflect company reporting, public sources and Reflexivity research as of 28 September 2026 and may change. Past performance is not indicative of future results.